Mechanistic basis of immunotherapies for type 1 diabetes mellitus

Translational Research

Volumn 161, Issue 4, 2013, Pages 217-229

  Chen, Wenhao ^a   Xie, Aini ^a   Chan, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD135 ANTIGEN; CHAPERONIN 60; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA VACCINE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUTAMATE DECARBOXYLASE 65; GRANULOCYTE COLONY STIMULATING FACTOR; GRANZYME; HEAT SHOCK PROTEIN 60 DIAPEP277; HLA A ANTIGEN; INSULIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OKT 3; OTELIXIZUMAB; PERFORIN; PREPROINSULIN; PROINSULIN; PROINSULIN II; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TEPLIZUMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLELE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BINDING AFFINITY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL PROTECTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVITY; GENE DELETION; GENE THERAPY; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HEREDITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERGLYCEMIA; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; INSULIN TREATMENT; INSULITIS; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 84875211293     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.12.017     Document Type: Review

References (154)

1. R.T. Wagner, J. Lewis, A. Cooney, and L. Chan Stem cell approaches for the treatment of type 1 diabetes mellitus Transl Res 156 2010 169 179
2. A. Banga, E. Akinci, L.V. Greder, J.R. Dutton, and J.M. Slack In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts Proc Natl Acad Sci U S A 109 2012 15336 15341
3. Q. Zhou, J. Brown, A. Kanarek, J. Rajagopal, and D.A. Melton In vivo reprogramming of adult pancreatic exocrine cells to beta-cells Nature 455 2008 627 632
4. V. Yechoor, V. Liu, and C. Espiritu Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes Dev Cell 16 2009 358 373
5. V. Yechoor, V. Liu, and A. Paul Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice Endocrinology 150 2009 4863 4873
6. B.O. Roep, and M. Peakman Diabetogenic T lymphocytes in human type 1 diabetes Curr Opin Immunol 23 2011 746 753
7. G.P. Lennon, M. Bettini, and A.R. Burton T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event Immunity 31 2009 643 653
8. X. Luo, K.C. Herold, and S.D. Miller Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32 2010 488 499
9. F. Waldron-Lynch, and K.C. Herold Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes Nat Rev Drug Discov 10 2011 439 452
10. T.K. Starr, S.C. Jameson, and K.A. Hogquist Positive and negative selection of T cells Annu Rev Immunol 21 2003 139 176
11. M.J. Bevan, K.A. Hogquist, and S.C. Jameson Selecting the T cell receptor repertoire Science 264 1994 796 797
12. J.A. Bluestone Mechanisms of tolerance Immunol Rev 241 2011 5 19
13. M.S. Anderson, and M.A. Su Aire and T cell development Curr Opin Immunol 23 2011 198 206
14. E.S. Husebye, and M.S. Anderson Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis Immunity 32 2010 479 487
15. M.S. Anderson, E.S. Venanzi, and L. Klein Projection of an immunological self shadow within the thymus by the aire protein Science 298 2002 1395 1401
16. S.T. Bennett, A.M. Lucassen, and S.C. Gough Susceptibility to human type 1diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus Nat Genet 9 1995 284 292
17. A. Pugliese, M. Zeller, and A. Fernandez The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes Nat Genet 15 1997 293 297
18. P. Vafiadis, S.T. Bennett, and J.A. Todd Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus Nat Genet 15 1997 289 292
19. Y. Fan, W.A. Rudert, M. Grupillo, J. He, G. Sisino, and M. Trucco Thymus-specific deletion of insulin induces autoimmune diabetes EMBO J 28 2009 2812 2824
20. J.A. Todd Etiology of type 1 diabetes Immunity 32 2010 457 467
21. A.G. Ziegler, and G.T. Nepom Prediction and pathogenesis in type 1 diabetes Immunity 32 2010 468 478
22. S. Nejentsev, J.M. Howson, and N.M. Walker Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A Nature 450 2007 887 892
23. J.M. Howson, N.M. Walker, D. Clayton, and J.A. Todd Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A Diabetes Obes Metab 11 Suppl 1 2009 31 45
24. A. Suri, J.J. Walters, M.L. Gross, and E.R. Unanue Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity J Clin Invest 115 2005 2268 2276
25. A.L. Corper, T. Stratmann, and V. Apostolopoulos A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes Science 288 2000 505 511
26. M.G. Levisetti, D.M. Lewis, A. Suri, and E.R. Unanue Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice Diabetes 57 2008 1852 1860
27. D. Zehn, and M.J. Bevan T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity Immunity 25 2006 261 270
28. A. Amrani, J. Verdaguer, P. Serra, S. Tafuro, R. Tan, and P. Santamaria Progression of autoimmune diabetes driven by avidity maturation of a T-cell population Nature 406 2000 739 742
29. J.P. Palmer, C.M. Asplin, and P. Clemons Insulin antibodies in insulin-dependent diabetics before insulin treatment Science 222 1983 1337 1339
30. S.C. Kent, Y. Chen, and L. Bregoli Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope Nature 435 2005 224 228
31. A. Skowera, R.J. Ellis, and R. Varela-Calvino CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope J Clin Invest 118 2008 3390 3402
32. D.G. Alleva, P.D. Crowe, and L. Jin A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin J Clin Invest 107 2001 173 180
33. J.H. Velthuis, W.W. Unger, and J.R. Abreu Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers Diabetes 59 2010 1721 1730
34. M. Nakayama, N. Abiru, and H. Moriyama Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice Nature 435 2005 220 223
35. J.F. Mohan, M.G. Levisetti, B. Calderon, J.W. Herzog, S.J. Petzold, and E.R. Unanue Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes Nat Immunol 11 2010 350 354
36. F.S. Wong, J. Karttunen, and C. Dumont Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library Nat Med 5 1999 1026 1031
37. H.L. Weiner, A.P. da Cunha, F. Quintana, and H. Wu Oral tolerance Immunol Rev 241 2011 241 259
38. S. Fourlanos, C. Perry, and S.A. Gellert Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes Diabetes 60 2011 1237 1245
39. J.S. Skyler, J.P. Krischer, and J. Wolfsdorf Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1 Diabetes Care 28 2005 1068 1076
40. K. Nanto-Salonen, A. Kupila, and S. Simell Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial Lancet 372 2008 1746 1755
41. N.R. Martinez, P. Augstein, and A.K. Moustakas Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide J Clin Invest 111 2003 1365 1371
42. D. Daniel, and D.R. Wegmann Intranasal administration of insulin peptide B: 9-23 protects NOD mice from diabetes Ann N Y Acad Sci 778 1996 371 372
43. D. Bresson, L. Togher, and E. Rodrigo Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs J Clin Invest 116 2006 1371 1381
44. T. Takiishi, H. Korf, and T.L. van Belle Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice J Clin Invest 122 2012 1717 1725
45. N. Solvason, Y.P. Lou, and W. Peters Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites J Immunol 181 2008 8298 8307
46. S. Prasad, A.P. Kohm, J.S. McMahon, X. Luo, and S.D. Miller Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading J Autoimmun 39 2012 347 353
47. C. Daniel, B. Weigmann, R. Bronson, and B.H. von Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope J Exp Med 208 2011 1501 1510
48. B. Krishnamurthy, J. Chee, and G. Jhala Complete diabetes protection despite delayed thymic tolerance in NOD8.3 TCR transgenic mice due to antigen-induced extrathymic deletion of T cells Diabetes 61 2012 425 435
49. B. Krishnamurthy, L. Mariana, and S.A. Gellert Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice J Immunol 180 2008 4458 4464
50. B. Krishnamurthy, N.L. Dudek, and M.D. McKenzie Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP J Clin Invest 116 2006 3258 3265
51. I. Jarchum, L. Nichol, M. Trucco, P. Santamaria, and T.P. Dilorenzo Identification of novel IGRP epitopes targeted in type 1 diabetes patients Clin Immunol 127 2008 359 365
52. M.I. Mally, V. Cirulli, T. Otonkoski, G. Soto, and A. Hayek Ontogeny and tissue distribution of human GAD expression Diabetes 45 1996 496 501
53. A. Hanninen, M. Soilu-Hanninen, and C.S. Hampe Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes Diabetes Metab Res Rev 26 2010 271 279
54. R. Tisch, X.D. Yang, S.M. Singer, R.S. Liblau, L. Fugger, and H.O. McDevitt Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice Nature 366 1993 72 75
55. J. Tian, M. Clare-Salzler, and A. Herschenfeld Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice Nat Med 2 1996 1348 1353
56. M. Schlosser, J.P. Banga, and A.M. Madec Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes Diabetologia 48 2005 922 930
57. N.E. Standifer, E.A. Burwell, V.H. Gersuk, C.J. Greenbaum, and G.T. Nepom Changes in autoreactive T cell avidity during type 1 diabetes development Clin Immunol 132 2009 312 320
58. J. Ludvigsson, M. Faresjo, and M. Hjorth GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 2008 1909 1920
59. J. Ludvigsson, D. Krisky, and R. Casas GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus N Engl J Med 366 2012 433 442
60. T.P. Dilorenzo Multiple antigens versus single major antigen in type 1 diabetes: arguing for multiple antigens Diabetes Metab Res Rev 27 2011 778 783
61. B.D. Stadinski, T. Delong, and N. Reisdorph Chromogranin A is an autoantigen in type 1 diabetes Nat Immunol 11 2010 225 231
62. S. Tsai, A. Shameli, and J. Yamanouchi Reversal of autoimmunity by boosting memory-like autoregulatory T cells Immunity 32 2010 568 580
63. A. Willcox, S.J. Richardson, A.J. Bone, A.K. Foulis, and N.G. Morgan Analysis of islet inflammation in human type 1 diabetes Clin Exp Immunol 155 2009 173 181
64. M.C. Gagnerault, J.J. Luan, C. Lotton, and F. Lepault Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice J Exp Med 196 2002 369 377
65. P. Hoglund, J. Mintern, C. Waltzinger, W. Heath, C. Benoist, and D. Mathis Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes J Exp Med 189 1999 331 339
66. S. Turley, L. Poirot, M. Hattori, C. Benoist, and D. Mathis Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model J Exp Med 198 2003 1527 1537
67. J.E. Smith-Garvin, G.A. Koretzky, and M.S. Jordan T cell activation Annu Rev Immunol 27 2009 591 619
68. T. Vang, M. Congia, and M.D. Macis Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant Nat Genet 37 2005 1317 1319
69. M. Rieck, A. Arechiga, S. Onengut-Gumuscu, C. Greenbaum, P. Concannon, and J.H. Buckner Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes J Immunol 179 2007 4704 4710
70. C. Ponticelli Cyclosporine: from renal transplantation to autoimmune diseases Ann N Y Acad Sci 1051 2005 551 558
71. C.R. Stiller, J. Dupre, and M. Gent Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset Science 223 1984 1362 1367
72. P.F. Bougneres, P. Landais, and C. Boisson Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin Diabetes 39 1990 1264 1272
73. K.L. Napoli, and P.J. Taylor From beach to bedside: history of the development of sirolimus Ther Drug Monit 23 2001 559 586
74. L. Piemonti, P. Maffi, and L. Monti Beta cell function during rapamycin monotherapy in long-term type 1 diabetes Diabetologia 54 2011 433 439
75. S.A. Long, M. Rieck, and S. Sanda Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function Diabetes 61 2012 2340 2348
76. L. Kjer-Nielsen, M.A. Dunstone, and L. Kostenko Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3 Proc Natl Acad Sci U S A 101 2004 7675 7680
77. A. Salmeron, F. Sanchez-Madrid, M.A. Ursa, M. Fresno, and B. Alarcon A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies J Immunol 147 1991 3047 3052
78. R.S. Gaston, M.H. Deierhoi, and T. Patterson OKT3 first-dose reaction: association with T cell subsets and cytokine release Kidney Int 39 1991 141 148
79. L. Chatenoud, and J.A. Bluestone CD3-specific antibodies: a portal to the treatment of autoimmunity Nat Rev Immunol 7 2007 622 632
80. K.C. Herold, J.B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, and J.A. Bluestone Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala) J Clin Invest 111 2003 409 418
81. M. Belghith, J.A. Bluestone, S. Barriot, J. Megret, J.F. Bach, and L. Chatenoud TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes Nat Med 9 2003 1202 1208
82. B. Bisikirska, J. Colgan, J. Luban, J.A. Bluestone, and K.C. Herold TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs J Clin Invest 115 2005 2904 2913
83. K.C. Herold, W. Hagopian, and J.A. Auger Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692 1698
84. K.C. Herold, S.E. Gitelman, and U. Masharani A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes Diabetes 54 2005 1763 1769
85. B. Keymeulen, E. Vandemeulebroucke, and A.G. Ziegler Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 2005 2598 2608
86. B. Keymeulen, M. Walter, and C. Mathieu Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 53 2010 614 623
87. K.C. Herold, S. Gitelman, and C. Greenbaum Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin Immunol 132 2009 166 173
88. N. Sherry, W. Hagopian, and J. Ludvigsson Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial Lancet 378 2011 487 497
89. F. Saudek, T. Havrdova, P. Boucek, L. Karasova, P. Novota, and J. Skibova Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset Rev Diabet Stud 1 2004 80 88
90. C.E. Couri, M.C. Oliveira, and A.B. Stracieri C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus JAMA 301 2009 1573 1579
91. J.C. Voltarelli, C.E. Couri, and A.B. Stracieri Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus JAMA 297 2007 1568 1576
92. J.W. Yoon, P.R. McClintock, T. Onodera, and A.L. Notkins Virus-induced diabetes mellitus. XVIII. Inhibition by a nondiabetogenic variant of encephalomyocarditis virus J Exp Med 152 1980 878 892
93. L. Wen, R.E. Ley, and P.Y. Volchkov Innate immunity and intestinal microbiota in the development of Type 1 diabetes Nature 455 2008 1109 1113
94. S. Nejentsev, N. Walker, D. Riches, M. Egholm, and J.A. Todd Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes Science 324 2009 387 389
95. P.M. Chilton, F. Rezzoug, and I. Fugier-Vivier Flt3-ligand treatment prevents diabetes in NOD mice Diabetes 53 2004 1995 2002
96. M. O'Keeffe, T.C. Brodnicki, and B. Fancke Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development Int Immunol 17 2005 307 314
97. B. Poligone, D.J. Weaver Jr., P. Sen, A.S. Baldwin Jr., and R. Tisch Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function J Immunol 168 2002 188 196
98. R.J. Steptoe, J.M. Ritchie, and L.C. Harrison Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice J Immunol 168 2002 5032 5041
99. H. Kared, A. Masson, H. Adle-Biassette, J.F. Bach, L. Chatenoud, and F. Zavala Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4+CD25+ regulatory T-cells Diabetes 54 2005 78 84
100. A. Mukhopadhaya, T. Hanafusa, and I. Jarchum Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice Proc Natl Acad Sci U S A 105 2008 6374 6379
101. P.J. Bingley Clinical applications of diabetes antibody testing J Clin Endocrinol Metab 95 2010 25 33
102. R. Mallone, and V. Brezar To B or not to B: (anti)bodies of evidence on the crime scene of type 1 diabetes? Diabetes 60 2011 2020 2022
103. H. Noorchashm, N. Noorchashm, J. Kern, S.Y. Rostami, C.F. Barker, and A. Naji B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice Diabetes 46 1997 941 946
104. P.A. Silveira, E. Johnson, H.D. Chapman, T. Bui, R.M. Tisch, and D.V. Serreze The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors Eur J Immunol 32 2002 3657 3666
105. D.V. Serreze, H.D. Chapman, and D.S. Varnum B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice J Exp Med 184 1996 2049 2053
106. C.Y. Hu, D. Rodriguez-Pinto, and W. Du Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice J Clin Invest 117 2007 3857 3867
107. M.D. Pescovitz, C.J. Greenbaum, and H. Krause-Steinrauf Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 2009 2143 2152
108. D. Zotos, J.M. Coquet, and Y. Zhang IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism J Exp Med 207 2010 365 378
109. M.P. Eggena, L.S. Walker, V. Nagabhushanam, L. Barron, A. Chodos, and A.K. Abbas Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen J Exp Med 199 2004 1725 1730
110. B.T. Fife, M.D. Griffin, A.K. Abbas, R.M. Locksley, and J.A. Bluestone Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist J Clin Invest 116 2006 2252 2261
111. H. Ueda, J.M. Howson, and L. Esposito Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease Nature 423 2003 506 511
112. T. Orban, B. Bundy, and D.J. Becker Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial Lancet 378 2011 412 419
113. N. Prevot, C. Briet, and H. Lassmann Abrogation of ICOS/ICOS ligand costimulation in NOD mice results in autoimmune deviation toward the neuromuscular system Eur J Immunol 40 2010 2267 2276
114. S.A. Nanji, W.W. Hancock, and B. Luo Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse Diabetes 55 2006 27 33
115. M. Kornete, E. Sgouroudis, and C.A. Piccirillo ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice J Immunol 188 2012 1064 1074
116. J.L. Riley PD-1 signaling in primary T cells Immunol Rev 229 2009 114 125
117. E.J. Wherry T cell exhaustion Nat Immunol 12 2011 492 499
118. M.J. Ansari, A.D. Salama, and T. Chitnis The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice J Exp Med 198 2003 63 69
119. J. Wang, T. Yoshida, F. Nakaki, H. Hiai, T. Okazaki, and T. Honjo Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes Proc Natl Acad Sci U S A 102 2005 11823 11828
120. M.E. Keir, S.C. Liang, and I. Guleria Tissue expression of PD-L1 mediates peripheral T cell tolerance J Exp Med 203 2006 883 895
121. T. Okazaki, I.M. Okazaki, and J. Wang PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice J Exp Med 208 2011 395 407
122. C. Wang, A.J. McPherson, and R.B. Jones Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection J Exp Med 209 2012 77 91
123. H.K. Sytwu, W.D. Lin, and S.R. Roffler Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model J Autoimmun 21 2003 247 254
124. A.L. Peters, L.L. Stunz, and G.A. Bishop CD40 and autoimmunity: the dark side of a great activator Semin Immunol 21 2009 293 300
125. G.A. Roth, A. Zuckermann, and W. Klepetko Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates Transplantation 78 2004 1238 1239
126. T. Hunig The storm has cleared: lessons from the CD28 superagonist TGN1412 trial Nat Rev Immunol 12 2012 317 318
127. M.A. Hulme, C.H. Wasserfall, M.A. Atkinson, and T.M. Brusko Central role for interleukin-2 in type 1 diabetes Diabetes 61 2012 14 22
128. J. Yamanouchi, D. Rainbow, and P. Serra Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity Nat Genet 39 2007 329 337
129. Q. Tang, J.Y. Adams, and C. Penaranda Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction Immunity 28 2008 687 697
130. Y. Grinberg-Bleyer, A. Baeyens, and S. You IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells J Exp Med 207 2010 1871 1878
131. S. Lindley, C.M. Dayan, A. Bishop, B.O. Roep, M. Peakman, and T.I. Tree Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes Diabetes 54 2005 92 99
132. C.A. Dendrou, V. Plagnol, and E. Fung Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource Nat Genet 41 2009 1011 1015
133. S.A. Long, K. Cerosaletti, and P.L. Bollyky Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-cells of type 1 diabetic subjects Diabetes 59 2010 407 415
134. J.M. Lawson, J. Tremble, and C. Dayan Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes Clin Exp Immunol 154 2008 353 359
135. A. Schneider, M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J.H. Buckner The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells J Immunol 181 2008 7350 7355
136. A.P. Sutherland, B.T. Van, and A.L. Wurster Interleukin-21 is required for the development of type 1 diabetes in NOD mice Diabetes 58 2009 1144 1155
137. H.M. McGuire, S. Walters, and A. Vogelzang Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models Diabetes 60 2011 867 875
138. H.M. McGuire, A. Vogelzang, and C.S. Ma A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity Immunity 34 2011 602 615
139. T.L. van Belle, S. Nierkens, R. Arens, and M.G. von Herrath Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets Immunity 36 2012 1060 1072
140. H. Elsaesser, K. Sauer, and D.G. Brooks IL-21 is required to control chronic viral infection Science 324 2009 1569 1572
141. J.S. Yi, M. Du, and A.J. Zajac A vital role for interleukin-21 in the control of a chronic viral infection Science 324 2009 1572 1576
142. A. Frohlich, J. Kisielow, and I. Schmitz IL-21R on T cells is critical for sustained functionality and control of chronic viral infection Science 324 2009 1576 1580
143. R. Spolski, and W.J. Leonard Interleukin-21: basic biology and implications for cancer and autoimmunity Annu Rev Immunol 26 2008 57 79
144. L. Zhou, Ivanov II, and R. Spolski IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways Nat Immunol 8 2007 967 974
145. T. Korn, E. Bettelli, and W. Gao IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells Nature 448 2007 484 487
146. R. Nurieva, X.O. Yang, and G. Martinez Essential autocrine regulation by IL-21 in the generation of inflammatory T cells Nature 448 2007 480 483
147. S. Arif, F. Moore, and K. Marks Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death Diabetes 60 2011 2112 2119
148. A.K. Marwaha, S.Q. Crome, and C. Panagiotopoulos Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes J Immunol 185 2010 3814 3818
149. J. Honkanen, J.K. Nieminen, and R. Gao IL-17 immunity in human type 1 diabetes J Immunol 185 2010 1959 1967
150. J.A. Emamaullee, J. Davis, and S. Merani Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice Diabetes 58 2009 1302 1311
151. K. Bendtzen, T. Mandrup-Poulsen, J. Nerup, J.H. Nielsen, C.A. Dinarello, and M. Svenson Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans Science 232 1986 1545 1547
152. K.M. Sumpter, S. Adhikari, E.K. Grishman, and P.C. White Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes Pediatr Diabetes 12 2011 656 667
153. V. Ablamunits, O. Henegariu, and J.B. Hansen Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation Diabetes 61 2012 145 154
154. A. Xia, E. Buras, J. Xia, and W. Chen The emerging role of interleukin-21 in transplantation J Clin Cell Immunol 2012 (in press)